India Mucormycosis Treatment (Black Fungus Drugs) Market, by Species (Rhizopus, Cunninghamella, Rhizomucor, Saksenaea, Apophysomyces, Lichtheimia, Mucor, and Others), by Diagnosis Method (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Tissue

India Mucormycosis Treatment (Black Fungus Drugs) Market, by Species (Rhizopus, Cunninghamella, Rhizomucor, Saksenaea, Apophysomyces, Lichtheimia, Mucor, and Others), by Diagnosis Method (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Tissue Biopsy, and Others), by Drugs (Amphotericin B, Isavuconazole, Posaconazole, Voriconazole, Flucytosine, Fluconazole, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Mucormycosis is a rapidly progressive and life-threatening invasive fungal disease with high morbidity and mortality rates despite treatment. It primarily affects immunocompromised patients such as those with organ and bone marrow transplantation, hematological malignancy, and patients with diabetes, cancer, neutropenia, and skin trauma. In rare cases it also affects immunocompetent patients. Mucormycosis is caused by a group of molds called mucormycetes. Inhaling the spores of the molds can affect the lungs and sinuses, and the fungus may also invade the skin through wounds such as cuts, burns, scrapes, or other types of skin trauma.
Market Dynamics

Major players in the market are indulged in inorganic activities such as collaborations with other market players, in order to launch anti-fungal drugs for the treatment of mucormycosis in the Indian population. This is expected to fuel growth of the India mucormycosis (black fungus) treatment market over the forecast period. For instance, on May 27, 2021, Strides Pharma Science Limited, a pharmaceutical company headquartered in Bangalore, India, are collaborating with TLC Pharma, a pharmaceutical company headquartered in Telangana, India, for launching TLC Pharma’s product AmphoTLC, a liposomal amphotericin B injection indicated for the treatment of various systemic fungal infections such as mucormycosis.
Different fungal species are involved for causing mucormycosis infection in Indian population. According to the article published in the Microorganism Journal, on March 4, 2021, the following graph shows the contribution of different species to mucormycosis burden in India (in percentage)


Key features of the study:
This report provides an in-depth analysis of India mucormycosis (black fungus) treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the India mucormycosis (black fungus) treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The India mucormycosis (black fungus) treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India mucormycosis (black fungus) treatment market
Detailed Segmentation:
India Mucormycosis (Black Fungus) Treatment Market, By Drugs:
Amphotericin B
Isavuconazole
Posaconazole
Voriconazole
Flucytosine
Fluconazole
Others
India Mucormycosis (Black Fungus) Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Natco Pharmaceuticals *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Alembic Pharmaceuticals
Gufic Biosciences
Lyca Pharmaceuticals
Emcure Pharmaceuticals
Bharat Serums and Vaccines
BDR Pharmaceuticals
Cipla Limited
Lifecare Innovations
Synbiotics Limited
Kamla Lifesciences
Cadila Healthcare Limited
TLC Pharma Labs

“*” marked represents similar segmentation in other categories in the respective section.